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ABSTRACT 
Cluster randomized trials are the gold standard for assessing efficacy of community-level 
interventions, such as vector control strategies against dengue. We describe a novel cluster 
randomized trial methodology with a test-negative design, which offers advantages over 
traditional approaches. It utilizes outcome-based sampling of patients presenting with a 
syndrome consistent with the disease of interest, who are subsequently classified as test-
positive cases or test-negative controls on the basis of diagnostic testing. We use simulations 
of a cluster trial to demonstrate validity of efficacy estimates under the test-negative 
approach. This demonstrates that, provided study arms are balanced for both test-negative 
and test-positive illness at baseline and that other test-negative design assumptions are met, 
the efficacy estimates closely match true efficacy. We also briefly discuss analytical 
considerations for an odds ratio-based effect estimate arising from clustered data, and 
outline potential approaches to analysis. We conclude that application of the test-negative 
design to certain cluster randomized trials could increase their efficiency and ease of 
implementation. 
KEY WORDS 
Case control; cluster randomized trial; dengue; efficacy; odds ratio; study design; test-
negative design; Wolbachia. 
ABBREVIATIONS 
CRT: Cluster randomized controlled trial; CR-TND: Cluster randomized trial with test-negative 
design sampling; TND: Test-negative design 
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Cluster randomized controlled trials (CRTs) are the gold standard for evaluating the efficacy 
of health interventions delivered at the community level, including vector control 
interventions to reduce transmission of arboviruses such as dengue and Zika. A recent 
literature review emphasized the need for quality randomized controlled trials to improve 
disease control strategies (1, 2). The importance of measuring impact on disease, not only on 
vector indices, has been specifically highlighted. However, it is widely accepted that trials 
using clinical endpoints can be resource intensive and logistically difficult to implement. 
CRTs customarily randomly allocate an intervention to some predefined spatial units, and 
follow a cohort of ‘at risk’ participants over time to measure the endpoint of interest in 
treated versus untreated clusters. When sufficient units are available, randomization results 
in groups comparable in all factors except for the intervention under study, and provides the 
basis for statistical inference (3). Such trials with epidemiological endpoints are resource 
intensive due to the requirement for active case surveillance. The non-independence of 
individuals within each cluster and resultant statistical inefficiency necessitates inflation of 
the CRT sample size to achieve power equivalent to an individually randomized trial (3-6). 
Traditional CRTs frequently require thousands of participants to generate sufficient events for 
hypothesis testing (7-12) particularly for interventions against uncommon events, e.g. 
clinically apparent dengue. This has significant cost, time, ethical and logistical implications. 
These challenges may partly account for the small number of cluster randomized controlled 
trials and subsequent weak evidence base for vector-control interventions against 
arboviruses (1), limiting evidence-based decision making for disease control. 
Considerable literature demonstrates that sampling participants on the basis of their 
outcome status (case-control design) rather than their exposure status (cohort design) 
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increases efficiency of observational studies (13-17). We propose a CRT study design with 
test-negative sampling (CR-TND), a form of outcome-based recruitment, as an efficient 
method to assess the efficacy of community-level interventions against dengue (such as 
introgression of Wolbachia into mosquito populations (18, 19)). The approach offers the 
advantage of being more efficient, cost-effective, and logistically simpler to achieve than a 
traditional CRT.  We review the assumptions inherent to the test-negative design (TND) and 
how these relate to its application in the context of a cluster randomized trial, use simulations 
to demonstrate the validity of estimates produced by a CR-TND study, and discuss potential 
approaches to analysis and interpretation of results. 
 
ASSUMPTIONS OF THE TEST-NEGATIVE DESIGN AND APPLICATION TO CRTs 
The TND is a modified case-cohort study in which symptomatic patients meeting pre-defined 
inclusion/exclusion criteria are enrolled and subsequently classified as test-positive ‘cases’ or 
test-negative ‘controls’ based on the results of definitive diagnostic testing. This design is 
frequently used for evaluating the effectiveness of seasonal influenza vaccination  (20-25) and 
its internal validity has been explored in depth (20-23, 26-28). Briefly, validity depends 
primarily upon the avoidance of selection bias in the sampling of cases and controls, and the 
extent to which the exposure distribution amongst controls is representative of the exposure 
distribution amongst the source population that gives rise to cases. Key assumptions and their 
relevance to CR-TND trials are discussed below. For ease of discussion we refer to the illness 
in those testing positive for the pathogen of interest as “test-positive illness”, and in those 
testing negative as “test-negative illness”. 
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Assumption 1. Test-negative illness is not associated with the intervention  
A core assumption of the TND is that the test-negative illness is not affected by the 
intervention (21, 22, 26); i.e. in the case of influenza VE studies, receipt of the influenza 
vaccine would not be expected to modify the incidence of non-influenza ARI. In randomized 
trials, random allocation of the intervention reduces the likelihood of any association 
between test-negative illness and the intervention. With an increasing number of clusters, 
the likelihood of test-negative illness occurring disproportionately in one study arm by chance 
is reduced. This may be particularly relevant where the test-negative illness is a 
communicable disease, as these tend to cluster in space and time. In cluster randomized trials 
with few allocation units, constrained randomization (29) can improve balance in factors 
potentially associated with test-positive or test-negative illness. Randomization thus 
represents a methodological advantage over influenza vaccine effectiveness studies in which 
self-selection may lead to an association between the intervention and outcome.  
Assumption 2. Non-differential probability of seeking health care 
Haber et al. (26) suggested the TND yields an unbiased estimate of effectiveness/efficacy even 
if the likelihood of seeking healthcare (and being enrolled) is associated with the intervention, 
provided this association exists for both test-positive and test-negative patients (26). Thus the 
TND may reduce bias due to intervention-driven changes to healthcare-seeking behavior 
relative to traditional cohort designs, a feature that may be particularly appealing in cluster 
randomized trials if blinding the community to intervention status is not feasible. A recent 
exploration of the theoretical basis of the TND in observational studies of influenza vaccine 
effectiveness (28) argued that the TND achieves a reduction in, rather than elimination of, 
bias due to healthcare-seeking behavior, since healthcare-seeking behavior represents a 
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continuous propensity rather than a simple binary variable that can be conditioned upon. 
Such potential bias should be further reduced in the CR-TND, since randomization of the 
intervention should achieve balance between study arms in individuals’ average propensity 
to seek healthcare. Constrained randomization can further enforce a balance between study 
arms in their baseline observed incidence of test-negative illness (that incorporates care-
seeking propensity as well as true disease incidence).  
Assumption 3.  The efficacy of the intervention is not associated with healthcare-seeking 
behavior 
The external validity of the TND depends on the intervention being equally effective across 
groups with different healthcare-seeking behavior, such that the effectiveness/efficacy 
estimate generated through a study of individuals presenting to clinics is generalizable to the 
broader population (21). A limitation to this assumption could arise in both TND and CR-TND 
studies if those more or less likely to seek care at a study clinic differ systematically in some 
factor associated with intervention effectiveness. For example, if socioeconomic status differs 
with healthcare-seeking behavior, this may correlate with differences in housing, vector 
density, community uptake of the intervention, or other factors that might impact the 
effectiveness of a dengue vector control intervention.  Tacitly, in extending effectiveness 
estimates to cases of all severity, we assume that the intervention does not modify the 
spectrum of disease outcomes. 
Assumption 4. The test used to determine disease status is highly sensitive and specific. 
Several authors (23, 26, 30) have modeled the effects of imperfect diagnostic testing on the 
TND estimate under different scenarios, demonstrating that a test (or combination of tests) 
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with imperfect sensitivity or specificity biases the estimate toward the null, with the greatest 
bias arising from imperfect specificity. This, of course, remains true with clustered 
participants since clustering affects variation and not bias. Thus TND or CR-TND studies that 
demonstrate effectiveness/efficacy even with imperfect test sensitivity and/or specificity will 
underestimate the true effect (23). Use of a consistent diagnostic algorithm, gold standard 
diagnostic tests, and with laboratory testing performed blind to exposure status, will minimize 
the potential for differential or non-differential outcome misclassification to bias the 
estimates from a TND or CR-TND study, in the same way as for other designs. 
Assumption 5. Uncensored sampling of controls 
The effect measure estimated from a retrospective study depends critically upon the criteria 
applied to the selection of controls (31, 32). If controls are drawn from all individuals in the 
population at risk, without exclusion of those who test positive at any other time during the 
study period (i.e. uncensored or inclusive sampling), then the exposure distribution in the 
controls can be assumed to reflect the exposure distribution in the source population. In that 
case the study provides a direct estimate of the population relative risk, without dependence 
on the rare disease assumption (32, 33), and, in this regard, a TND most resembles a case-
cohort design. If controls are sampled inclusively as above, and also longitudinally throughout 
the study period concurrently with cases (incidence-density or risk-set sampling), then their 
cumulative exposure distribution represents that of the source population at each point in 
time (‘risk period’) that a case arose. If this temporal matching is accounted for in the analysis, 
then the odds ratio directly estimates a population incidence rate ratio (31, 33, 34).  
In the case of a (cluster randomized) test-negative design study, patients presenting to 
participating clinics with a test-negative illness are assumed to represent a sample of the 
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source population from which cases arise, i.e. the population who would present to these 
clinics and be enrolled as a case if they experienced a test-positive illness. Foppa et al. (25) 
have demonstrated that TND studies using incidence density sampling produce valid 
estimates of effect even when the incidence of test-positive or test-negative illness varies 
temporally. Because calendar time may correlate also with the exposure distribution (e.g. 
influenza vaccination uptake), analyses of observational TND studies have often included 
adjustment for calendar time (21). In the analysis of a CR-TND study, a participant’s exposure 
to the intervention is considered fixed and non-time varying for the purpose of the intention-
to-treat analysis, as per the randomized allocation, in which case time adjustment is not 
warranted. A per-protocol analysis, however, may account for individuals’ time-varying 
exposure to the intervention and require adjustment for calendar time. 
Assumption 6.  Participants with test-negative illness are only recruited when test-positive 
illness is circulating 
An extension of assumption 5 in the case of a seasonal illness is that, in order to achieve 
incidence density sampling of test-positive and test-negative participants, recruitment should 
only occur during periods when test-positive illness is circulating (21). Outside the 
transmission season there is effectively no ‘population at risk’ of test-positive illness, and 
therefore test-negative controls recruited during this period are not a valid sample of the 
source population from which test-positive cases arise. This principle holds also for CR-TND 
studies. In practice, if a study is to run over more than one transmission season it may be 
infeasible to stop and start patient recruitment, or the beginning and end of the transmission 
periods may not be easily predicted in advance. This criterion can still be met while allowing 
continuous recruitment, by restricting the dataset for analysis to include only those test-
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negative controls enrolled during periods in which there were also test-positive participants 
recruited. 
Finally, we note that many of the concerns regarding the TND raised by careful consideration 
of biases (27, 28, 35) are mitigated, or removed, by exposure randomization in a CR-TND. For 
example, randomization essentially removes the impact of differential misclassification of 
disease outcome within levels of extraneous factors (28) since the latter are balanced across 
arms. In addition, in the case of an infectious disease where spatio-temporal heterogeneity 
could lead to differences in baseline risk of illness between clusters, randomization of a 
sufficient number of clusters will ensure the overall risk of illness remains balanced between 
study arms. The causal diagrams relevant to TNDs (specifically directed acyclic graphs: DAGs) 
(28) apply here directly but are simplified as no arrows point into the (randomly assigned) 
intervention node; clustering of response does not affect a DAG. Further, randomization of 
exposure removes bias from estimation of marginal odds ratio measures of association (27). 
The non-collapsibility of the odds ratio (27) applies here to the extent that an intervention’s 
effect at a cluster level may be greater than the population effect; however, this means that 
the latter measure will simply be conservative. Later, in the paper we show that basic 
estimation procedures for CRTs and TNDs can be straightforwardly extended to CR-TND study 
data.  
 
SIMULATIONS 
We assessed the validity of efficacy estimates generated through a CR-TND using simulations 
and found accurate and unbiased estimates are produced, provided the randomization 
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achieves balance between study arms at baseline in both the outcome of interest and the 
test-negative illness, and other assumptions of the TND are met.  We simulated scenarios to 
compare the CR-TND efficacy estimate against the true efficacy of a hypothetical preventive 
intervention against dengue (Web Figure 1). Initially we assumed the intervention had no 
effect. Hypothetical study populations were generated, consisting of 20-100 clusters, each 
with a random population size drawn from a uniform distribution with range 5000 to 25,000. 
Baseline dengue and test-negative illness incidence rates in each cluster were simulated 
based on independent Beta distributions, and applied to cluster population sizes to yield case 
counts for each category (Web Figure 2). Parameter choices for test-negative illness incidence 
were selected to yield two distinct values of the inter-cluster coefficient of variation (k), k = 
0.5 and 0.25; k was set at 0.5 for dengue incidence. The rate parameters were selected to 
mimic dengue case notification rates (36-38) and k values (39) from southeast Asian dengue 
endemic settings. Note that any co-variation of dengue and test-negative case counts arises 
solely from common cluster population sizes.  
We randomly allocated half the clusters to receive the intervention. We performed simple 
randomization, plus three constrained randomizations in which we generated a large number 
of potential random allocations and accepted only those in which the baseline i) dengue 
incidence, ii) test-negative illness incidence or iii) both dengue and test-negative illness 
incidence were balanced between arms, defined as a difference of ≤10% in aggregate 
incidence. 
We calculated the exposure odds ratio (OR) in dengue vs test-negative controls for each 
random allocation, using the standard formula:  
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OR = 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 𝑐𝑐𝑐𝑐𝑐𝑐𝑑𝑑𝑐𝑐 𝑖𝑖𝑑𝑑 𝑖𝑖𝑑𝑑𝑖𝑖𝑑𝑑𝑖𝑖𝑖𝑖𝑑𝑑𝑑𝑑𝑖𝑖𝑖𝑖𝑖𝑖𝑑𝑑 𝑐𝑐𝑖𝑖𝑎𝑎
𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 𝑐𝑐𝑐𝑐𝑐𝑐𝑑𝑑𝑐𝑐 𝑖𝑖𝑑𝑑 𝑑𝑑𝑖𝑖𝑑𝑑−𝑖𝑖𝑑𝑑𝑖𝑖𝑑𝑑𝑖𝑖𝑖𝑖𝑑𝑑𝑑𝑑𝑖𝑖𝑖𝑖𝑖𝑖𝑑𝑑 𝑐𝑐𝑖𝑖𝑎𝑎  / 𝑖𝑖𝑑𝑑𝑐𝑐𝑖𝑖−𝑑𝑑𝑑𝑑𝑑𝑑𝑐𝑐𝑖𝑖𝑖𝑖𝑖𝑖𝑑𝑑 𝑐𝑐𝑖𝑖𝑑𝑑𝑖𝑖𝑖𝑖𝑖𝑖𝑐𝑐𝑐𝑐 𝑖𝑖𝑑𝑑 𝑖𝑖𝑑𝑑𝑖𝑖𝑑𝑑𝑖𝑖𝑖𝑖𝑑𝑑𝑑𝑑𝑖𝑖𝑖𝑖𝑖𝑖𝑑𝑑 𝑐𝑐𝑖𝑖𝑎𝑎𝑖𝑖𝑑𝑑𝑐𝑐𝑖𝑖−𝑑𝑑𝑑𝑑𝑑𝑑𝑐𝑐𝑖𝑖𝑖𝑖𝑖𝑖𝑑𝑑 𝑐𝑐𝑖𝑖𝑑𝑑𝑖𝑖𝑖𝑖𝑖𝑖𝑐𝑐𝑐𝑐 𝑖𝑖𝑑𝑑 𝑑𝑑𝑖𝑖𝑑𝑑−𝑖𝑖𝑑𝑑𝑖𝑖𝑑𝑑𝑖𝑖𝑖𝑖𝑑𝑑𝑑𝑑𝑖𝑖𝑖𝑖𝑖𝑖𝑑𝑑 𝑐𝑐𝑖𝑖𝑎𝑎 . 
For simplicity, we assumed complete sampling of dengue (test-positive) cases and test-
negative controls from both study arms, perfect diagnostic test sensitivity and specificity, and 
that all assumptions of the TND were met. Thus the only variation across simulations was in 
cluster intervention assignment. We repeated each simulation 1,000 times for each 
combination of the number of clusters and inter-cluster coefficient of variation. The 
percentage deviation from the expected null value (i.e. OR=1) was assessed for each 
simulation (Figure 1). 
Results demonstrate that the odds ratio estimated through a CR-TND study approximates the 
true null value. Random variation around the null is particularly reduced when study arms are 
balanced for both test-positive and test-negative illness baseline incidence. Such variation 
also decreases as the number of study clusters increases and at the lower value of inter-
cluster heterogeneity for test-negative illness incidence. With balance on historical incidence 
of both dengue and test-negative outcomes, estimation is effective even with small numbers 
of clusters (Figure 1D). 
We further investigated validity of the odds ratio estimates assuming a true intervention 
efficacy of 50%, by repeating the above steps while deterministically halving dengue incidence 
in each intervention cluster. The deviation of the simulation-derived odds ratio estimates 
from the expected ‘true’ value was identical for an assumed efficacy of 50% (Web Figure 3) 
and at the null (Figure 1).   
 
ANALYSIS OF CLUSTER RANDOMIZED TEST-NEGATIVE DESIGN STUDIES 
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Community-level interventions introduce additional complexity into analysis of a CR-TND 
compared to an observational TND study, while allowing inference to be based on 
randomization. With test-negative designs, vaccine effectiveness is usually estimated through 
the odds ratio as defined above (21).  Logistic regression models allow adjustment for 
potential confounders (20, 40) including calendar time. Common adjustments are time-
matching using a conditional logistic regression model, or inclusion of calendar week as a 
categorical parameter using splines in an unconditional model  (40). For a CR-TND, however, 
any analysis needs to account for the clustering. We note two possible approaches that adapt 
procedures commonly used for CRTs. 
(a) Cluster-level Summary Data: We can simply use the estimated odds ratio based on 
data aggregated across all clusters, with the null hypothesis that the odds of being in the 
intervention arm is the same among test-positives as test-negatives. Inference can be based 
on the permutation distribution that considers all possible cluster intervention assignments. 
An approximate version of this test uses an estimate of the variance of the estimated odds 
ratio that accounts for the clustering using simple finite population sampling ideas (41).  
The aggregate odds ratio provides a consistent estimate of the relative risk, albeit at a 
population-averaged, or marginal, level (41). (This is in contrast to a cluster-specific odds ratio 
that is, in general, further from the null than the marginal version—see (3); the difference is 
not of practical concern with rare outcomes). Confidence intervals can either be based on 
inverting the permutation test or via the approximate variance formula (41).  
An alternative summary efficacy measure is based on the proportion of test-positive patients 
(amongst all tested individuals) in each cluster. At the null, the average of these proportions 
should be the same in both arms. For testing, the average of these proportions for the 
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intervention clusters can then be compared to the same for control clusters via the t-statistic, 
with inference based on a permutation test again, or on an approximate variance (41).  
This approach also provides an estimate of the (cluster-specific) relative risk (RR). Specifically, 
with 2m clusters (m assigned to intervention), the expected proportion of test-positives in the 
intervention clusters is approximately 𝑅𝑅𝑅𝑅
𝑅𝑅𝑅𝑅+(𝑟𝑟
2
)(1+𝑅𝑅𝑅𝑅) , and 11+(𝑟𝑟
2
)(1+𝑅𝑅𝑅𝑅) for the control clusters, 
where the ratio of sampled controls to cases is r. For example, if r = 1 and RR = 0.5, the average 
proportion of test-positives in a treated cluster is 2/5 (0.40) and 4/7 (0.57) in a control cluster. 
These calculations assume that the intervention effect is identical in all treated clusters. The 
difference in these average proportions of test-positives between intervention and control 
clusters yields an estimate of the relative risk since we can substitute the estimated difference 
in the proportions, d, into the formula 𝑑𝑑 = 1
1+(𝑟𝑟
2
)(1+𝑅𝑅𝑅𝑅) − 𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅+(𝑟𝑟
2
)(1+𝑅𝑅𝑅𝑅), yielding a quadratic 
equation for RR. This yields an estimate of RR, along with an appropriately transformed 
confidence interval (from that for d) (41).  
Note that Generalized Estimating Equations estimates of the odds ratio that use robust 
variances do not perform well in situations where there are relatively few clusters. On the 
other hand, random effects logistic regression performs better and may provide a third 
alternative approach with sufficient clusters available (41).  
(b) Individual-level analysis: In the CR-TND a form of ‘per-protocol’ analysis is likely 
of interest, to reduce the potential impact of exposure misclassification arising from the fact 
that some individuals in an intervention cluster may spend substantial time in a control cluster 
and vice-versa. This ‘contamination’ would necessarily reduce the observed effect of the 
intervention. Available measurements on such mobility contemporaneous to symptoms 
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would then be included in an analysis that allows for individual-level covariates, in addition 
to calendar time as previously discussed.  
Modifications to the permutation distribution techniques used for either the odds ratio or the 
difference in average test-positive proportions across clusters, may be developed by 
extending similar approaches for standard cluster randomized trials (42-44). In addition, 
covariates can be introduced straightforwardly into a random effects logistic regression 
model. Incorporating calendar time in this way effectively fits a proportional hazards frailty 
model if one assumes that the intervention effect is constant over time.   
 
DISCUSSION 
Public health strategies to control dengue and other arboviruses lack a robust evidence base 
due to the absence of well-powered cluster randomized trials of community-level 
interventions with disease endpoints (2).  The absence of such trials might reflect the common 
belief that mosquito population suppression must inevitably lead to lower disease incidence, 
yet this relationship is poorly characterized and unlikely to be linear (45, 46).  Additionally, 
there is a perception that cluster randomized trials require fever surveillance of pre-defined 
cohorts of ‘at risk’ individuals and that such efforts must always be logistically and financially 
demanding. Here we propose that cluster randomized trials with test-negative design 
sampling offer increased efficiency and validity by recruiting participants based on their 
outcome, rather than exposure status. Advantages include a smaller total sample size and 
potentially single rather than repeat contact with study participants, as well as avoidance of 
potential biases that can arise in longitudinal studies from under-ascertainment of illness 
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events or loss to follow-up. A primary advantage of the CR-TND approach over traditional 
TNDs is the randomization of the intervention that reduces confounding and provides a firm 
basis for inference. The CR-TND therefore represents an attractive novel design for trials of 
community-based interventions against acute infectious diseases such as dengue. 
The key assumption underlying the validity of CR-TND effect estimates is that the ratio of 
exposed to unexposed patients with test-negative illness is an unbiased estimate of the ratio 
of exposed to unexposed persons in the source population who would seek health care if they 
developed the test-negative (or test-positive) illness. This assumption could be violated if an 
inappropriate test-negative illness was selected, upon which the intervention has a true 
effect. For example, in the case of a dengue vector control intervention trial, another Aedes-
borne pathogen such as Zika or chikungunya must be excluded from the classification of test-
negative illness because the intervention could also feasibly modify the distribution of these 
diseases.  Furthermore, small numbers of clusters limit the power of the design. Our 
simulations indicate that constrained randomization may be useful to increase precision, 
particularly when the number of clusters under study is small. 
The outcome-based sampling in a CR-TND uses an odds ratio as the estimate of effect, the 
interpretation of which depends on the criteria applied in sampling test-negative controls. 
When controls are sampled concurrently with cases and without regard for past or future 
test-positive illness, as is proposed here, the odds ratio of exposure in test-positive vs test-
negative patients yields a direct estimate of the relative risk in the source population. If the 
temporal matching of test-positives and test-negatives is accounted for in the analysis, then 
this becomes an unbiased estimate of the rate ratio , and thus the CR-TND can produce an 
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equivalently intuitive and valid effect estimate as a traditional longitudinal CRT design but 
with potentially substantial savings in time and resources (41). 
In addition to its efficiency benefits, the outcome-based sampling employed in the CR-TND 
also has a potential advantage over traditional study designs in reducing biases that can arise 
through longitudinal follow-up where the ascertainment of disease endpoints relies on 
passive case detection of study participants presenting to clinics when ill. Such designs carry 
a risk of misclassification bias, as any cohort members with the disease of interest who fail to 
present to a study clinic, or to be identified upon presentation, are falsely classified as disease-
free (21). Loss-to-follow up that is differential between study arms and/or outcome status is 
another potential source of bias in traditional longitudinal designs, particularly when follow-
up periods are long. The health care-seeking behaviour of the population, if differential 
between treatment arms e.g. with a non-blinded intervention, can also confound the 
observed association between intervention and outcome (21). These biases are avoided in 
the CR-TND through the sampling of test-negative controls from the same patient population 
as the test-positive cases, and because of the random assignment of the intervention. CRTs 
of community interventions are susceptible to exposure misclassification if participants’ 
mobility patterns lead to contamination between intervention and control clusters. The CR-
TND allows for inclusion of a per-protocol analysis employing more nuanced exposure 
classification based on recall of movements just prior to illness onset, which would not be 
possible in e.g. a prospective serological cohort with sampling at annual or six-monthly 
intervals. 
A key challenge to implementation of the CR-TND, compared with an observational TND, is 
adaptation of analytical methods to account adequately for clustering of participants with 
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respect to their intervention allocation status. We have elsewhere proposed methods to 
accommodate clustering in group-level analysis of intervention effect, using a permutation 
approach to statistical inference (41). Published CRT formulae for sample size calculations are 
inadequate for the CR-TND, and simulation studies based on baseline data, best estimates, or 
pilot studies are needed to assess the required sample size (41). Even for CRTs, sample size 
calculations need preliminary estimates of design effects induced by the clustering, 
information that is often poorly reported.  
Both the accuracy of sample size estimations, and the benefits conferred by constraining 
randomization to only those allocations in which balance is achieved in both test-negative 
and test-positive illness incidence, depend on the availability of reliable baseline data, and 
the degree to which historical patterns are likely to reflect the future illness distribution. The 
spatial and temporal variability in many infectious diseases, and their propensity to cluster in 
space and time, could lead to a different distribution being observed during the study period 
compared to baseline. The incidence rate ratio of test-negative illness between treated and 
untreated arms during the study period should therefore be reported; this should 
approximate one if the assumption of no relationship between intervention and test-negative 
illness is upheld. Re-estimation of power/sample size at an interim time point after study 
commencement – using the trial data from the control arm to determine inter-cluster 
heterogeneity of test-positive and test-negative illness – may also be advisable to affirm the 
estimates based on historical data. 
The study design described here extends the test-negative design to cluster-randomized 
intervention trials. We have demonstrated that valid estimates of effect are produced by the 
CR-TND, even with a relatively small number of clusters, particularly when constrained 
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randomization is employed to ensure balance in baseline test-positive and test-negative 
illness, and assuming the core assumptions of the TND are upheld. This design offers potential 
for improving the efficiency of cluster randomized trials of preventive interventions, including 
for arboviral diseases such as dengue and Zika, through targeted clinic-based enrolment and 
testing of patients with a specified disease syndrome instead of longitudinal follow-up of large 
cohorts. Other public health applications in which the CR-TND could prove valuable include 
the evaluation of mass drug administration for parasitic infections, and estimation of both the 
direct and indirect (‘herd’) effects of vaccine-derived immunity in the context of vaccine trials 
or observational studies, subject to first establishing that the assumptions outlined here are 
upheld. 
Further extensions to this work will refine the approaches to statistical inference and sample 
size estimation, and develop methods for individual-level analysis that allow adjustment for 
individual covariates such as time of recruitment or non-binary exposure status due to 
mobility or heterogeneous coverage of the intervention. Extension to non-parallel 
randomized allocations will also be explored, for example where a community-level 
intervention is deployed using a stepped-wedge design. The first field implementation of the 
CR-TND, to our knowledge, will be a cluster randomized controlled trial to assess the efficacy 
of Wolbachia-infected mosquito deployments against dengue in Yogyakarta, Indonesia 
(ClinicalTrials.Gov #NCT03055585; (47)). This will provide a valuable opportunity to test both 
the feasibility and validity of the design in practice, generating learnings to inform improved 
design of trials to evaluate preventive interventions for vector-borne diseases and other 
public health priorities. 
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FIGURE LEGENDS 
Figure 1. Validity of odds ratio estimates from a simulated CR-TND study, under the null 
hypothesis of no intervention effect. Box and whiskers plots show the distribution of odds 
ratio estimates from 1000 simulated cluster-randomized allocations of a hypothetical 
dengue preventive intervention, displayed as the % deviation from the expected OR=1 
assuming that the true intervention efficacy is zero. The ten different scenarios within each 
graph represent a variable number of clusters under study (20 – 100) and two scenarios of 
the inter-cluster coefficient of variation (k) in baseline test-negative illness incidence: high 
(H; k=0.5) or low (L; k=0.25). Inter-cluster variation in baseline dengue incidence was 
constant in all scenarios (k=0.5). Random allocation of the intervention was either 
unconstrained (A), or constrained to ensure balance between the study arms (+/- 10%) in 
baseline dengue incidence (B), test-negative illness incidence (C), or both dengue and test-
negative illness incidence (D). Note that five OR estimates from Panel A (4/1000 simulations 
with 20 clusters & high k, and 1/1000 simulation with 20 clusters & low k) and two OR 
estimates in Panel C (2/1000 simulations with 20 clusters & low k) had a deviation value less 
than -150% and are not shown on the graph. 
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WEB MATERIAL: 
Web Figure 1: Summary of simulation methods. k: inter-cluster coefficient of variation 
(standard deviation/mean). 
Web Figure 2: Characteristics of hypothetical study populations. Histograms show the 
distributions of population per cluster (A), test-positive illness (dengue) incidence per 100,000 
population (B), test-negative illness incidence per 100,000 population under the scenario of 
greater heterogeneity with coefficient of variation k=0.5 (C), and test-negative illness incidence 
per 100,000 population under the scenario of less heterogeneity with k=0.25 (D), for each 
hypothetical study population used in the simulations, where the total number of clusters was 
20, 40, 60, 80 or 100 (graph parts i-v). 
Web Figure 3: Validity of odds ratio estimates from a simulated CR-TND study, assuming a 
true intervention efficacy of 50%. Box and whiskers plots show the distribution of odds ratio 
(OR) estimates from 1000 simulated cluster-randomized allocations of a hypothetical dengue 
preventive intervention, displayed as the % deviation from the expected OR=0.5 assuming that 
the true intervention efficacy is 50%. The ten different scenarios within each graph represent a 
variable number of clusters under study (20 – 100) and two scenarios of inter-cluster 
coefficient of variation (k) in baseline test-negative illness incidence: high (H; k=0.5) or low (L; 
k=0.25). Inter-cluster variation in baseline dengue incidence was constant in all scenarios 
(k=0.5). Random allocation of the intervention was either unconstrained (A), or constrained to 
ensure balance between the study arms (+/- 10%) in baseline dengue incidence (B), test-
negative illness incidence (C), or both dengue and test-negative illness incidence (D). Note that 
five OR estimates from Panel A (4/1000 simulations with 20 clusters & high k, and 1/1000 
simulation with 20 clusters & low k) and two OR estimates in Panel C (2/1000 simulations with 
20 clusters & low k) had a deviation value less than -150% and are not shown on the graph. 
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60 971,950 210 104.3 0.50 210 105.0 0.50 210 53.1 0.25
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Web Figure 3: Validity of odds ratio estimates from a simulated CR-TND study, assuming a true intervention efficacy of 50%. 
